Search Results for "therapeutic"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

HELIOS-A: Impact of Vutrisiran on Quality of Life and Functional Status in Hereditary Transthyretin Mediated Amyloidosis with Polyneuropathy

Chronic symptoms reported by patients with acute hepatic porphyria in the POWER study in a subgroup analysis of nonrecurrent patients

Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyria: 36-Month Results of the Phase 3 ENVISION Randomized Clinical Trial

APOLLO Post-Hoc Analysis by Baseline Polyneuropathy Severity

A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.

Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life

Effects of Vutrisiran on Measures of Cardiac Structure, Function and Amyloid Burden by Cardiovascular Magnetic Resonance from the HELIOS-B Trial

Healthcare resource utilization for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan

Impact of Vutrisiran on Activities of Daily Living and Functional Status in Patients with hATTR Amyloidosis

Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B

Baseline characteristics from BONAPH1DE: A global, observational, longitudinal study of patients with primary hyperoxaluria type 1

ENVISION study EQ-5D analysis to assess relationship between annualized attack rate with expanded criteria and chronic symptoms in patients with acute hepatic porphyria

Dimension analysis of ENVISION study EQ-5D data to assess relationship between annualized attack rate and chronic symptoms in patients with acute hepatic porphyria

Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study

KARDIA-3: A randomized trial of zilebesiran versus placebo on top of standard care for patients with hypertension and established cardiovascular disease or high cardiovascular risk with or without chronic kidney disease

Long-term treatment with lumasiran: final results from the phase 2 open-label extension study

Lumasiran for Primary Hyperoxaluria Type 1: Analysis of Urinary Oxalate and eGFR Over Time in Patients With and Without Baseline Pyridoxine Use

Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children

Healthcare Resource Utilization and Costs Among Patient Segments with Acute Intermittent Porphyria: Analyses from a National Healthcare Database

Long-term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Final Analysis of the ILLUMINATE-A Trial

Kidney Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Treated With Long-term Lumasiran

Annualized attack rate reductions vs historical data and hemin use of patients with acute hepatic porphyria in phase 3 ENVISION trial who were not attack-free after 6 months of givosiran treatment

Long-Term Lumasiran Treatment, Kidney Function, and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1

Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment

TRITON-CM: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Neurofilament Light Chain in ATTR Amyloidosis with Cardiomyopathy: Analysis from the Phase 3 APOLLO-B Study

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.